[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

April 27, 2017
Original Investigation

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction CancerThe AIO-FLOT3 Trial

Abstract Full Text
JAMA Oncol. Published online April 27, 2017. doi:10.1001/jamaoncol.2017.0515

This phase 2 trial assesses the effect of neoadjuvant chemotherapy followed by surgery on survival in patients with metastatic gastric and gastroesophageal junction cancer.

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Abstract Full Text
JAMA Oncol. Published online April 27, 2017. doi:10.1001/jamaoncol.2017.0589

This population-based study evaluates SEER data on the incidence and prevalence of neuroendocrine tumors over 20 years.

Brief Report

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer

Abstract Full Text
JAMA Oncol. Published online April 27, 2017. doi:10.1001/jamaoncol.2017.0502

This case-control study using 2 cohorts attempts to identify the genetic variants associated with cisplatin-induced ototoxic effects in adult patients with testicular cancer.

Invited Commentary

Understanding Neuroendocrine Tumors—A NET Gain

Abstract Full Text
JAMA Oncol. Published online April 27, 2017. doi:10.1001/jamaoncol.2017.0575
Comment & Response

Inferior Survival Rates After Chemoradiation for Rectal Cancer Without Surgery

Abstract Full Text
JAMA Oncol. Published online April 27, 2017. doi:10.1001/jamaoncol.2016.6618

Inferior Survival Rates After Chemoradiation for Rectal Cancer Without Surgery—Reply

Abstract Full Text
JAMA Oncol. Published online April 27, 2017. doi:10.1001/jamaoncol.2017.0407

Erroneous Sentence in Cancer Care Chronicles Article

Abstract Full Text
JAMA Oncol. Published online April 27, 2017. doi:10.1001/jamaoncol.2017.1363
Correction

Erroneous Sentence Removed From Article

Abstract Full Text
free access
JAMA Oncol. Published online April 27, 2017. doi:10.1001/jamaoncol.2017.1368
Poetry and Oncology

Sickness

Abstract Full Text
JAMA Oncol. Published online April 27, 2017. doi:10.1001/jamaoncol.2017.0476
April 20, 2017
Viewpoint

Affordability of Cancer Drugs in Sub-Saharan AfricaEffects of Pricing on Needless Loss of Life

Abstract Full Text
JAMA Oncol. Published online April 20, 2017. doi:10.1001/jamaoncol.2017.0479

This Viewpoint cites instances of how the availability of lifesaving cancer drugs in sub-Saharan Africa are increasing overall survival to argue for the increased dissemination of cost-effective or free cancer drugs.

Original Investigation

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive GlioblastomaA Phase 1 Dose-Escalation Trial

Abstract Full Text
JAMA Oncol. Published online April 20, 2017. doi:10.1001/jamaoncol.2017.0184

This open-label phase 1 dose-escalation study examines whether systemic administration of HER2-specific chimeric antigen receptor–modified virus-specific T cells is safe and whether these cells have antiglioblastoma activity.

Brief Report

Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors

Abstract Full Text
JAMA Oncol. Published online April 20, 2017. doi:10.1001/jamaoncol.2017.0465

This cohort study assessed the survival impact of second primary malignant neoplasms (SMPs) in adolescents and young adults compared with that of children and older adults with the same SPMs.

Research Letter

Association of Patient Age With Outcomes of Current-Era, Large-Scale Screening MammographyAnalysis of Data From the National Mammography Database

Abstract Full Text
JAMA Oncol. Published online April 20, 2017. doi:10.1001/jamaoncol.2017.0482

This study analyzes mammography screening data from the National Mammography Database to determine the age cutoff point for screening.

April 13, 2017
Editorial

Multigene Panel Testing and Breast Cancer RiskIs It Time to Scale Down?

Abstract Full Text
JAMA Oncol. Published online April 13, 2017. doi:10.1001/jamaoncol.2017.0342
Original Investigation

Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology

Abstract Full Text
JAMA Oncol. Published online April 13, 2017. doi:10.1001/jamaoncol.2017.0123

This study analyzes how patient preferences and burden of disease can be incorporated into randomized clinical trials in oncology using Bayesian decision analysis and the impact that these factors have on statistical thresholds for drug approval.

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer

Abstract Full Text
JAMA Oncol. Published online April 13, 2017. doi:10.1001/jamaoncol.2017.0424

This case-control study evaluates pathogenic variants in panel genes tested in women with breast cancer.

Comment & Response

Tumor Sidedness and Prognosis in Colorectal CancerIs Microbiome the Missing Link?

Abstract Full Text
JAMA Oncol. Published online April 13, 2017. doi:10.1001/jamaoncol.2017.0034
April 6, 2017
Original Investigation

Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention

Abstract Full Text
JAMA Oncol. Published online April 6, 2017. doi:10.1001/jamaoncol.2017.0223

This longitudinal registry study assesses the clinical spectra and age-related penetrance in individuals with pheochromocytomas and paragangliomas and mutations in the SDHA, TMEM127, MAX, and SDHAF2 genes.

Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant TumorsA Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online April 6, 2017. doi:10.1001/jamaoncol.2017.0324

This randomized clinical trial compares the effects of metronomic chemotherapy on progression-free survival vs placebo in pediatric patients with primary extracranial, nonhematopoietic solid malignant tumors that progress after at least 2 lines of chemotherapy.

Brief Report

Characterizing 18 Years of the Death With Dignity Act in Oregon

Abstract Full Text
JAMA Oncol. Published online April 6, 2017. doi:10.1001/jamaoncol.2017.0243

This study examines trends in patient utilization of physician-aided dying under the Death With Dignity Act in Oregon between 1998 and 2015.

Invited Commentary

Pheochromocytoma and Paraganglioma Susceptibility GenesEstimating the Associated Risk of Disease

Abstract Full Text
JAMA Oncol. Published online April 6, 2017. doi:10.1001/jamaoncol.2017.0222
×